As of the end of 2025, Novartis employed some 5,720 full-time-equivalent scientists, physicians and business professionals in ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the ...

Alumis is exploring strategic alternatives for its would-be rival to Amgen’s Tepezza, choosing to punt the program rather ...

Aardvark Therapeutics is planning to unblind data from its phase 3 Prader-Willi syndrome (PWS) program after the FDA put a ...

Tech provider Signant Health announced the acquisition of Ametris to unite its electronic clinical outcome assessments (eCOA) ...

As the wave of in vivo CAR-T hype crests, Create Medicines is catching the swell with a $122 million series B meant to back ...

Regenxbio’s gene therapy for Duchenne muscular dystrophy has smashed the primary endpoint of its pivotal trial, securing a ...

A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...

After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit ...

Valneva is planning to shrink its headcount by up to 15% as the French vaccine developer continues to seek ways to cut costs.

Global contract research organization Icon has announced the opening of a new research facility in San Antonio, Texas, along ...

Takeda has ended development of its nausea and vomiting drug candidate for strategic reasons, continuing its multi-year ...